More on Cepheid (CPHD): Q3 beats on a per share basis with revenue largely in-line with...
More on Cepheid (CPHD): Q3 beats on a per share basis with revenue largely in-line with estimates. Net losses were $21.3M, or -$0.32 per share, largely due to litigation settlement charges. Results were also affected by a buildup in back orders due to intermittent interruption in availability of certain plastic parts used in the production of its Xpert cartridges, which prevented the fulfillment of all test cartridge orders in the quarter.
Check out Seeking Alpha’s new Earnings Center »
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs